238 Trial - Nivolumab as Standard for Melanoma Therapeutics Available for Relapsed Immunotherapy
Omid Hamid MD <br />Chief, Translational Research/Immuno-Oncology<br />Director explains, 238 Trial - Nivolumab as Standard for Melanoma Therapeutics Available for Relapsed Immunotherapy at the 2018 Oncolog...
Author: moasc
Added: 03/08/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts